HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.

Abstract
The activity of phosphohexose isomerase [PHI] was measured in 48 primary carcinomas from patients with breast cancer, and its usefulness as a predictor of response to cytotoxic drugs at the metastatic stage was evaluated. There was a statistically significant difference in the activity of PHI between responders and non-responders to these treatments. These preliminary findings are currently being evaluated in an extended series.
AuthorsI Mitchell, N Deshpande, R Millis, R D Rubens
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 17 Issue 3 Pg. 289-91 ( 1986) ISSN: 0344-5704 [Print] Germany
PMID3742715 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Glucose-6-Phosphate Isomerase
Topics
  • Antineoplastic Agents (therapeutic use)
  • Breast Neoplasms (drug therapy, enzymology)
  • Glucose-6-Phosphate Isomerase (metabolism)
  • Humans
  • Neoplasm Metastasis
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: